Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Cl

Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others)

The Europe microbiome therapeutics market was valued at US$ 97.74 million in 2022 and is expected to reach US$ 212.52 million by 2030; it is estimated to record a CAGR of 10.2% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives Europe Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of 13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

Europe Microbiome Therapeutics Market Overview

Microbiome therapeutic research companies in Germany are focused on calling other companies to invest in their research activities to improve the quality of research being conducted for microbiome product development. In March 2023, mbiomics GmbH, a German biotech company focused on the microbiome, received ~US$ 15 million (13 million) in a series A financing round led by MIG Capital. mbiomics used the proceeds to embark on strategic partnerships, significantly expanding their Munich laboratory facilities and R&D teams in Germany. In some FMT procedures, infectious agents may be transferred from donor to patient, which affects the outcomes. Hence, Germany has set particular regulations for the use of microbiome or FMT procedures. In Germany, FMT drugs are regulated as a medicinal product; however, the use of this product can be done only when no other treatment is working on conditions such as C. difficile infections and gut infections. Hence, despite an upsurge in investments in research on microbiome therapeutics, regulations regarding the use of these therapeutic products may hamper the growth of the Europe microbiome therapeutics market in Germany.

Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Microbiome Therapeutics Market Segmentation

The Europe microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The metabolic disorder and obesity segment held the largest share in 2022.

By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe microbiome therapeutics market in 2022.

Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA are some of the leading companies operating in the Europe microbiome therapeutics market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe microbiome therapeutics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Please Note: It will take 3-5 business days to complete the report upon order confirmation for delivery of the full report and excel data pack for on demand reports. Show more